Sign In
Buy CLRB
$2.57
+0.0400 (+1.58%)
At Close: Jul 31, 2026
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024
06:40am, Tuesday, 07'th May 2024
FLORHAM PARK, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercializ
Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript
12:27pm, Wednesday, 27'th Mar 2024
Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
06:40am, Wednesday, 27'th Mar 2024
FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercial
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
06:40am, Wednesday, 20'th Mar 2024
FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercial
Cellectar Biosciences to Present at the 36th Annual Roth Conference
08:52am, Thursday, 14'th Mar 2024
FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercial
FLORHAM PARK, N.J., March 04, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commerci
Cellectar Biosciences: A Shoestring Opportunity You're About To Miss
01:34am, Monday, 12'th Feb 2024
Cellectar Biosciences is a developmental biotech focused on a radiolabeled phospholipid for hematologic malignancies, with a focus on Waldenstrom's macroglobulinemia. Their most advanced development i
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
06:40am, Wednesday, 07'th Feb 2024
FLORHAM PARK, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commerciali
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study
06:40am, Tuesday, 30'th Jan 2024
Study of Iopofosine I 131 Supported by $2 Million Grant from the National Institute of Health's National Cancer Institute (NCI) Study of Iopofosine I 131 Supported by $2 Million Grant from the Nationa
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million
06:40am, Thursday, 25'th Jan 2024
FLORHAM PARK, N.J., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializ
Iopofosine I 131 Active in Treating Malignancies in the Brain; Confirmed Response in CNS Lymphoma Provides Additional Validation for Continued Development of Iopofosine in Multiple CNS Malignancies Io
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data
06:40am, Tuesday, 16'th Jan 2024
Proprietary TAT Phospholipid Conjugate Demonstrates Potent Activity in Resistant Pancreatic Cancer Initiating IND-enabling Studies for First-in-Human Phase I Clinical Study FLORHAM PARK, N.J., Jan. 16
Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D.
06:44am, Friday, 12'th Jan 2024
Dr. Levy to Provide Perspective on Iopofosine I 131's Potential in the Community Clinic Treatment Landscape of Waldenstrom's Macroglobulinemia Dr. Levy to Provide Perspective on Iopofosine I 131's Pot
Partnership to Provide Key Data on WM Treatment Landscape and Community Clinic Access to Support Iopofosine I 131 Commercialization Strategy Partnership to Provide Key Data on WM Treatment Landscape a
Why Is Cellectar Biosciences (CLRB) Stock Up 16% Today?
08:37am, Monday, 08'th Jan 2024
Cellectar Biosciences (NASDAQ: CLRB ) stock is heading higher on Monday after the company posted positive results from its CLOVER WaM study of iopofosine I 131. According to a press release from the
